Misiu: Yes GILD is in deep trouble: - KITE acqu
Post# of 148299
- KITE acquisition has not paid the amount of money they invested.
- They have failed with their candidate for NASH
- TRUVADA is now generic and they need to replace (Descovy).
- Has strong competition in ViiV
- GILD is basically now a single-product company (TAF-based products).
- Has greatly under-invested in HIV research.
The solution: Leronlimab !!!!